vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more
vTv Therapeutics Inc (VTVT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.074x
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has a cash flow conversion efficiency ratio of -0.074x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.22 Million) by net assets ($70.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
vTv Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how vTv Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
vTv Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of vTv Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polight ASA
OL:PLT
|
-0.042x |
|
B Communications Ltd
PINK:BCOMF
|
0.050x |
|
Sapura Energy Bhd
KLSE:5218
|
-0.224x |
|
Tanvex BioPharma Inc
TW:6541
|
-0.037x |
|
GalaxiaMoneytree Co.Ltd
KQ:094480
|
-0.044x |
|
Niko Semiconductor Co Ltd
TWO:3317
|
0.018x |
|
Nova Klúbburinn hf.
IC:NOVA
|
N/A |
|
India Motor Parts and Accessories Limited
NSE:IMPAL
|
0.005x |
Annual Cash Flow Conversion Efficiency for vTv Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of vTv Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.30 Million | $-25.31 Million | -1.770x | -272.03% |
| 2023-12-31 | $-18.55 Million | $-19.08 Million | 1.029x | +139.40% |
| 2022-12-31 | $5.84 Million | $-15.25 Million | -2.611x | -105.85% |
| 2021-12-31 | $15.22 Million | $-19.31 Million | -1.268x | +73.27% |
| 2020-12-31 | $3.79 Million | $-18.00 Million | -4.746x | -282.25% |
| 2019-12-31 | $-8.84 Million | $-23.02 Million | 2.604x | +703.31% |
| 2018-12-31 | $-82.85 Million | $-26.86 Million | 0.324x | +9.88% |
| 2017-12-31 | $-151.05 Million | $-44.56 Million | 0.295x | -44.35% |
| 2016-12-31 | $-90.94 Million | $-48.21 Million | 0.530x | +11.87% |
| 2015-12-31 | $-77.97 Million | $-36.95 Million | 0.474x | +667.92% |
| 2014-12-31 | $-498.81 Million | $-30.78 Million | 0.062x | -55.04% |
| 2013-12-31 | $-303.73 Million | $-41.68 Million | 0.137x | -- |